Bristol-Myers Squibb Posts New Data on Combination of Investigational Compounds BMS-790052 and BMS-650032 for the Treatment of Chronic Hepatitis C

PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE: BMY) today posted to the company website an overview of new, phase II data on the combination therapy of two small molecule antivirals in development for the treatment of chronic hepatitis C -- BMS-790052, an NS5A inhibitor, and BMS-650032, an NS3 protease inhibitor -- alone or with pegylated interferon and ribavirin. The data were presented today at the 61 st Annual Meeting of the American Association for the Study of the Liver Diseases in Boston. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews . Bristol-Myers SquibbMedia:Cristi Barnett, [email protected]:John Elicker, [email protected]

The release as fetched from its publisher. bms.com ↗